rethinkTHC Search
Menu
Study breakdown

Boosting the Endocannabinoid 2-AG Enhanced Cue-Triggered Nicotine Seeking in Mice

Animal StudyPreliminary evidence
The takeaway

Inhibiting the enzyme that breaks down the endocannabinoid 2-AG did not affect nicotine self-administration or motivation but significantly enhanced cue-induced reinstatement of nicotine seeking, implicating 2-AG in tobacco relapse.

Read this if you are interested in the biological mechanisms of nicotine cravings and relapse.

MAGL inhibition enhanced cue-induced nicotine seeking without affecting ongoing nicotine use or motivation.

What the researchers found

Researchers tested whether boosting 2-AG levels (by inhibiting its breakdown enzyme MAGL with JZL184) would affect nicotine-related behaviors in mice.

MAGL inhibition had no effect on active nicotine self-administration, motivation for nicotine (progressive ratio), or food self-administration. However, the high dose (16 mg/kg) significantly enhanced cue-induced reinstatement of previously extinguished nicotine seeking. Importantly, JZL184 did not produce reinstatement on its own.

This pattern means that 2-AG does not seem to affect the ongoing rewarding effects of nicotine but amplifies the ability of nicotine-associated cues (sights, sounds, situations previously paired with smoking) to trigger relapse-like behavior.

Why it matters

Relapse triggered by environmental cues is one of the primary challenges in tobacco cessation. This study identifies the endocannabinoid 2-AG as a modulator of this cue-driven relapse process. If 2-AG amplifies cue reactivity, then blocking 2-AG production or action could potentially reduce cue-triggered cravings for tobacco.

The numbers in context

JZL184 at 8 and 16 mg/kg did not affect nicotine self-administration or progressive-ratio breakpoints. JZL184 at 16 mg/kg significantly enhanced cue-induced reinstatement. No effect on food self-administration.

How the study worked

Mouse study using intravenous nicotine self-administration under fixed-ratio and progressive-ratio schedules. JZL184 (0, 8, 16 mg/kg) was tested for effects on nicotine taking, motivation, and cue-induced reinstatement of extinguished nicotine seeking. Food self-administration was tested as a control for non-specific effects.

What this study cannot tell us

Mouse study with limited sample size. Only one MAGL inhibitor was tested. The cue-induced reinstatement model, while validated, is an approximation of human relapse. The effect was seen only at the higher dose, raising questions about dose-response. JZL184 affects 2-AG globally, not in specific brain regions.

How to read the evidence

Preliminary evidence from an animal study with a clear and specific behavioral finding, though the mechanism needs further investigation.

When this study was published

Published in 2016. The role of 2-AG in addiction-related behaviors continues to be explored.

The bigger picture

The endocannabinoid system is increasingly recognized as a modulator of drug relapse. This study adds specificity: 2-AG appears to selectively enhance cue-driven seeking without affecting ongoing drug use or motivation. This dissociation is valuable for understanding different aspects of addiction and could inform targeted therapeutic approaches.

Questions still open

  • Would MAGL inhibitors increase relapse risk in smokers trying to quit? Could MAGL inhibition be used therapeutically in reverse, by pairing it with extinction training to enhance learning that cues are no longer predictive? Which brain regions mediate the 2-AG effect on cue reactivity?

Common questions

How does the endocannabinoid system affect nicotine cravings?
This study found that boosting 2-AG (an endocannabinoid) amplified the ability of nicotine-associated cues to trigger drug-seeking behavior in mice. This suggests the endocannabinoid system may modulate how strongly environmental triggers drive tobacco cravings.
Could this help with quitting smoking?
Potentially, but in reverse. If 2-AG enhances cue-driven cravings, then reducing 2-AG signaling might dampen the power of environmental triggers to provoke relapse. This therapeutic approach has not been tested yet.

Read the original research

Inhibition of monoacylglycerol lipase (MAGL) enhances cue-induced reinstatement of nicotine-seeking behavior in mice.

Psychopharmacology, 233(10), 1815-22

Citation

Trigo, Jose M; Le Foll, Bernard. (2016). Inhibition of monoacylglycerol lipase (MAGL) enhances cue-induced reinstatement of nicotine-seeking behavior in mice.. Psychopharmacology, 233(10), 1815-22. https://doi.org/10.1007/s00213-015-4117-5

Explore the wider topic